8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV

4. Chronic Obstructive Pulmonary Disease (COPD): GOLD Staging & Stable Management

COPD is characterized by persistent, progressive, non-fully reversible airflow limitation arising from a combination of small airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema). Cigarette smoking is the predominant etiology, causing chronic neutrophilic and macrophage-mediated inflammation with release of matrix metalloproteinases and neutrophil elastase.

Spirometric Confirmation & GOLD Staging

Diagnosis requires post-bronchodilator spirometry confirming airflow obstruction with $\text{FEV}_1/\text{FVC} < 0.70$. The severity of airflow limitation is graded by post-bronchodilator $\text{FEV}_1$ percentage predicted:

• GOLD 1 (Mild): $\text{FEV}_1 \ge 80\%$ predicted.
• GOLD 2 (Moderate): $50\% \le \text{FEV}_1 < 80\%$ predicted.
• GOLD 3 (Severe): $30\% \le \text{FEV}_1 < 50\%$ predicted.
• GOLD 4 (Very Severe): $\text{FEV}_1 < 30\%$ predicted.

GOLD Refined Assessment Framework (Groups A, B, E)

The 2023/2024 GOLD guidelines consolidated high exacerbation risk into Group E:

• Group A: 0–1 moderate exacerbations not requiring hospital admission; low symptom burden (mMRC dyspnoea score 0–1 or CAT score $< 10$). Treatment: Initial bronchodilator (SABA, LABA, or LAMA).
• Group B: 0–1 moderate exacerbations; high symptom burden (mMRC $\ge 2$ or CAT $\ge 10$). Treatment: First-line dual long-acting bronchodilators (LABA + LAMA combination, e.g., vilanterol/umeclidinium, formoterol/glycopyrronium, or olodaterol/tiotropium).
• Group E (Exacerbation Risk): $\ge 2$ moderate exacerbations or $\ge 1$ exacerbation resulting in hospital admission. Treatment: First-line LABA + LAMA. If peripheral blood eosinophil count is $\ge 300\text{ cells/}\mu\text{L}$, initiate Triple Therapy (LABA + LAMA + ICS) immediately. In patients on LABA + LAMA who develop recurrent exacerbations with blood eosinophils $\ge 100\text{ cells/}\mu\text{L}$, escalate to triple therapy. (The landmark IMPACT and ETHOS trials demonstrated that triple therapy significantly reduces moderate-to-severe exacerbations and improves all-cause survival compared to LABA/LAMA in this group).

Non-Pharmacological Interventions

• Smoking Cessation: The single most effective disease-modifying intervention. Normal rate of $\text{FEV}_1$ decline ($25\text{–}30\text{ mL/year}$) accelerates to $60\text{–}90\text{ mL/year}$ in active smokers; cessation slows the decline back to age-related physiological rates.
• Pulmonary Rehabilitation: Indicated for patients with an MRC dyspnoea score $\ge 3$ or following an acute hospital admission for AECOPD. A structured 6–12 week multidisciplinary exercise training and educational programme proven to improve exercise endurance, reduce breathlessness, and lower hospital readmission rates.
• Long-Term Oxygen Therapy (LTOT):
  • Assessed only when the patient is clinically stable on maximal therapy for $\ge 5$ weeks post-exacerbation.
  • Absolute Criteria: Resting ambient air $\text{PaO}_2 < 7.3\text{ kPa}$ ($< 55\text{ mmHg}$).
  • Relative Criteria: Resting $\text{PaO}_2$ between $7.3\text{ and } 8.0\text{ kPa}$ ($55\text{–}60\text{ mmHg}$) in the presence of secondary polycythaemia (haematocrit $\ge 55\%$), clinical or echocardiographic evidence of pulmonary hypertension, peripheral oedema (cor pulmonale), or documented nocturnal hypoxaemia.
  • Must be utilized for $\ge 15\text{ hours/day}$ (including sleep) to provide a statistically significant mortality benefit. Strictly prohibited in active smokers due to severe facial burn and domestic fire hazards.

---

5. Acute Exacerbations of COPD (AECOPD) & Non-Invasive Ventilation (NIV)

An acute exacerbation of COPD is characterized by acute worsening of respiratory symptoms (dyspnoea, cough, sputum volume, and purulence) beyond normal day-to-day variations, predominantly precipitated by respiratory viral or bacterial infections (Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Pseudomonas aeruginosa).

Controlled Oxygen Delivery: Avoiding Hypercapnic Coma

• Patients with severe COPD have chronic ventilation-perfusion (V/Q) mismatching. Administering unregulated high-flow oxygen precipitates acute hypercapnia via three distinct pathophysiological mechanisms:
  1. Reversal of Hypoxic Pulmonary Vasoconstriction: High alveolar oxygen causes vasodilation in poorly ventilated lung units, dramatically increasing physiological dead space ($V_D/V_T$). (This is the dominant mechanism, contributing $> 70\%$ of the rise in $\text{PaCO}_2$).
  2. The Haldane Effect: Oxygenation of deoxygenated haemoglobin reduces its affinity for $\text{CO}_2$, displacing $\text{CO}_2$ from carbamino compounds into plasma, raising dissolved blood $\text{PaCO}_2$.
  3. Blunting of Ventilatory Drive: Modest reduction in carotid body chemoreceptor stimulation.
• Clinical Practice: Administer oxygen via a $24\%$ or $28\%$ Venturi mask (or nasal cannulae at $1\text{–}2\text{ L/min}$) strictly targeting an oxygen saturation of $88\text{–}92\%$. Repeat an arterial blood gas (ABG) within 30 to 60 minutes.

Pharmacotherapy of AECOPD

• Bronchodilators: Nebulised salbutamol ($2.5\text{–}5\text{ mg}$) and ipratropium bromide ($500\ \mu\text{g}$) driven by compressed medical air (NOT cylinder oxygen; oxygen-driven nebulisers deliver $100\%\ \text{FiO}_2$ and induce fatal hypercapnia).
• Corticosteroids: Oral prednisolone $30\text{ mg}$ once daily for 5 days (prolonged courses offer no additional benefit and increase adverse events).
• Antibiotics: Indicated if the patient exhibits increased sputum purulence or requires mechanical ventilation. First-line oral choices: amoxicillin ($500\text{ mg}$ tds), doxycycline ($200\text{ mg}$ stat then $100\text{ mg}$ od), or clarithromycin ($500\text{ mg}$ bd) for 5 days.

Non-Invasive Ventilation (NIV / BiPAP)

• Primary Indication: Acute hypercapnic respiratory failure (Type 2) secondary to COPD exacerbation with persistent respiratory acidosis (defined as $\text{pH } 7.25\text{–}7.35$ and $\text{PaCO}_2 > 6.0\text{ kPa}$) persisting after 1 hour of optimal medical management and controlled oxygen therapy.
• Physiological Action: Delivers Inspiratory Positive Airway Pressure (IPAP, typically starting at $10\text{–}12\text{ cmH}_2\text{O}$ and titrated to $16\text{–}20\text{ cmH}_2\text{O}$) to assist diaphragmatic work and augment tidal volume, reducing $\text{PaCO}_2$. Expiratory Positive Airway Pressure (EPAP, typically $4\text{–}5\text{ cmH}_2\text{O}$) prevents small airway collapse and overcomes intrinsic PEEP (PEEPi).
• Absolute/Relative Contraindications: Respiratory arrest, Glasgow Coma Scale $< 8$ (unless hypercapnic coma where an immediate trial under close supervision is warranted), facial burns/trauma, bowel obstruction, severe uncontrolled vomiting, undrained pneumothorax, or severe hemodynamic instability requiring vasopressors.

---

6. BTS/SIGN Asthma Management vs. GOLD COPD Staging & Regimens